Skip to main content


Latest articles

14-05-2021 | Rheumatology | News | Article

Real-world effectiveness may vary with adalimumab biosimilars

The adalimumab biosimilars GP2107 and SB5 may differ in their rates of discontinuation and remission in routine clinical practice, researchers report.

14-05-2021 | Rheumatology | News | Article

Early data do not show fecal microbiota transplantation benefit in peripheral PsA

Findings from a proof-of-concept study suggest that fecal microbiota transplantation may not be a suitable option for patients with active peripheral psoriatic arthritis but further investigation is still needed.

13-05-2021 | Rheumatology | News | Article

COAST-Y supports continued ixekizumab treatment for patients with axSpA

Patients with axial spondyloarthritis who continue treatment with ixekizumab are less likely to experience flares than those who discontinue the IL-17A inhibitor, trial results suggest.

12-05-2021 | Rheumatology | News | Article

​​​​​​​EULAR issues recommendations on self-management strategies for inflammatory arthritis

Click through for more details

12-05-2021 | Rheumatology | News | Article

NOR-DRUM, ARCTIC REWIND trials evaluate tailored DMARD strategies

Findings from two Norwegian trials published in JAMA do not support routine therapeutic drug monitoring with biologics or dose reduction of conventional DMARDs in patients with inflammatory diseases.

11-05-2021 | Rheumatology | News | Article

Rituximab treatment ‘may not preclude’ COVID-19 vaccination

Findings from a small study suggest that rituximab-treated patients with depleted B cells may be able to mount a T cell-mediated immune response to COVID-19 vaccination, despite having an impaired antibody response.

10-05-2021 | Rheumatology | Highlight | Article

People with inflammatory diseases may have impaired antibody response to COVID-19 vaccination

SARS-CoV-2 vaccination “essentially works” in people with immune-mediated inflammatory diseases, but humoral immune responses may be delayed and reduced, researchers report.

07-05-2021 | Rheumatology | News | Article

Biologic treatment spacing feasible for some rheumatic disease patients

Patients with rheumatic diseases who have stable disease remission or low disease activity might be able to reduce their biologic DMARD treatment without disease flare by spacing their doses, BIOPURE findings show.

06-05-2021 | Rheumatology | News | Article

COVID-19: Control of inflammation ‘seems to be key’ in patients with rheumatic diseases

Findings from the Euro-COVIMID study suggest that the seroprevalence and effects of SARS-CoV-2 infection in patients with rheumatic diseases are in line with those in the general population, and inflammation may be a risk factor for developing symptomatic COVID-19.

05-05-2021 | Rheumatology | News | Article

COVID-19 thrombosis not linked to lupus anticoagulant positivity

Individuals with COVID-19 have a high prevalence of lupus antigen positivity upon hospital admission, but this is not associated with an increased risk for venous thromboembolism or in-hospital mortality, French researchers report.

04-05-2021 | Rheumatology | News | Article

Etanercept retreatment feasible in people with JIA

Etanercept is effective in the retreatment of patients with juvenile idiopathic arthritis who have a disease flare after previously achieving inactive disease on the biologic DMARD, research suggests.

30-04-2021 | Rheumatology | News | Article

Clinical differences in baricitinib and tofacitinib effectiveness in rheumatoid arthritis

Patients with rheumatoid arthritis may derive better clinical outcomes from baricitinib than tofacitinib in the first 24 weeks of treatment, especially if they have previously received multiple biologic DMARDs, show real-world data.

29-04-2021 | Rheumatology | News | Article

People with vasculitis have elevated risk for COVID-19, influenza mortality

Study findings presented at the online British Society for Rheumatology 2021 Annual Conference suggest that people with vasculitis have an elevated mortality risk during COVID-19 and influenza outbreaks.

29-04-2021 | Rheumatology | News | Article

​​​​​​​COVID-19 outcomes described in children with rheumatic diseases taking biologics

An analysis of children with rheumatic diseases undergoing treatment with biologic agents has found no severe cases of COVID-19.

28-04-2021 | Rheumatology | News | Article

PASDAS best reflects disease activity, treatment response in psoriatic arthritis

A comparison of different composite measures suggests that PASDAS has the strongest ability to predict disease activity and treatment response in patients with oligoarticular or polyarticular psoriatic arthritis.

28-04-2021 | Rheumatology | News | Article

Suboptimal prescribing of osteoporosis medications in people with polymyalgia rheumatica

Less than half of patients with polymyalgia rheumatica are prescribed medications for osteoporosis, despite clinical guidelines recommending bone protection for those on long-term glucocorticoid treatment, research suggests.

27-04-2021 | Rheumatology | News | Article

Predictors of methotrexate-related adverse events described in RA patients

Research presented at the online British Society for Rheumatology 2021 Annual Conference has identified predictors of adverse events in people with rheumatoid arthritis receiving treatment with methotrexate.

26-04-2021 | Rheumatology | News | Article

Age, sex may influence baricitinib discontinuation rates in rheumatoid arthritis

Real-world study results suggest that the majority of baricitinib-treated patients with rheumatoid arthritis remain on the JAK inhibitor after a year, with older age and female sex associated with treatment persistence.

26-04-2021 | Rheumatology | News | Article

Rheumatology clinics provide an opportunity to address smoking

Protocols for discussing smoking habits, attitudes, and risks in rheumatology clinics may increase referral rates to US state-run tobacco quit lines, research suggests.

23-04-2021 | Rheumatology | News | Article

Treat-to-target urate lowering regimen feasible in most people with gout

A urate lowering treat-to-target approach combined with personalized advice can help the majority of patients with gout achieve satisfactory serum urate levels, but some modifiable barriers to target fulfillment still exist, Norwegian researchers report.

Image Credits